Tularik and Amgen in Oncology Agreement
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 37 (Table of Contents)
Published: 3 Jun-2003
DOI: 10.3833/pdr.v2003.i37.890 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Tularik and Amgen entered into 5-year research and development agreement to discover, develop and commercialize oncology therapeutics including T67, a small molecule that binds to beta-tubulin that is in phase II clinical trials for the treatment of hepatocellular carcinoma and T607, which is in phase II clinical trials for the treatment of hepatocellular carcinoma, ovarian cancer, gastric cancer and esophageal cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS